SCHEMBL6517545

SCHEMBL6517545

N#Cc1cccc(CNc2ccc3c(=O)[nH]c4ncccc4c3c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.53
CCNT1 O60563 2/20 0.48
CDK9 P50750 2/20 0.48
AURKA O14965 1/20 0.47
PARP1 P09874 1/20 0.47
BRD4 O60885 1/20 0.44
MAP3K8 P41279 1/20 0.43
VNN1 O95497 3/20 0.43
ROCK2 O75116 3/20 0.43
CYP3A4 P08684 2/20 0.42
ROCK1 Q13464 1/20 0.42
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NOS1 P29475 1/20 0.40
HDAC4 P56524 1/20 0.40
MEF2D Q14814 1/20 0.40
IP6K1 Q92551 1/20 0.40
NTRK1 P04629 1/20 0.40
NTRK3 Q16288 1/20 0.40
NTRK2 Q16620 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3454371 0.84 AURKA (0.60) CDK9AURKAPARP1BRD4ROCK2
SCHEMBL6519127 0.84 CDC7 (0.51) CCNT1CDK9AURKAPARP1ROCK2
SCHEMBL6523494 0.84 AURKA (0.50) CCNT1CDK9AURKAPARP1IP6K1
SCHEMBL6517978 0.84 CDC7 (0.52) AURKAPARP1ROCK2CYP3A4CYP2C19
SCHEMBL6518254 0.83 AURKA (0.52) AURKAPARP1BRD4
SCHEMBL12846396 0.83 PARP1 (0.49) CCNT1CDK9AURKAPARP1BRD4
SCHEMBL6516089 0.82 AURKA (0.54) CCNT1CDK9AURKAPARP1CYP3A4
SCHEMBL6517544 0.81 FGFR1 (0.51) CCNT1CDK9AURKAPARP1ROCK2
SCHEMBL3454238 0.81 ROCK2 (0.54) AURKAPARP1BRD4ROCK2ROCK1
SCHEMBL6522266 0.81 AURKA (0.55) CCNT1CDK9AURKAPARP1IP6K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 LRRK2 411/4885CCNT1 1341/4885CDK9 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.